Treating Kidney Cancer: Updates on Adjuvant Therapy for Advanced Renal Cell Carcinoma by Dr. Taylor

19 Visioni

Grazie! Condividilo con i tuoi amici!

Non hai gradito questo video. Grazie per il feedback!

Published Jan 30, 2026

Jennifer M. Taylor, MD, MPH, Baylor College of Medicine, presents an in-depth discussion on adjuvant therapy for advanced renal cell carcinoma (RCC). She focuses on the role of pembrolizumab as the only FDA-approved adjuvant immunotherapy following nephrectomy for patients at high risk of recurrence.

The presentation highlights results from the KEYNOTE-564 trial, which demonstrate durable disease-free and overall survival benefits with adjuvant pembrolizumab. Dr. Taylor compares these outcomes with prior tyrosine kinase inhibitor (TKI) trials, discussing differences in trial design, patient selection, and tolerability. She also reviews emerging biomarkers such as kidney injury molecule 1 (KIM-1) and circulating tumor DNA (ctDNA) as potential tools for improving treatment selection.

Dr. Taylor notes that adjuvant pembrolizumab is the current standard of care for high-risk, non-metastatic RCC, emphasizing multidisciplinary collaboration in postoperative management. #RCC #Pembrolizumab #AdjuvantTherapy #KidneyCancer #UrologyEducation #GrandRoundsInUrology

Don't forget to join the GRU Community: https://grandroundsinurology.com/register/
Follow us on Twitter/X: https://x.com/GRUrology
And like and subscribe to us here on YouTube!